Cognition Therapeutics, Inc. (CGTX) Earnings History
Annual and quarterly earnings data from 2019 to 2025
Loading earnings history...
CGTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CGTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export CGTX earnings history in CSV or JSON format
Free sign-in required to download data
Cognition Therapeutics, Inc. (CGTX) Earnings Overview
As of May 8, 2026, Cognition Therapeutics, Inc. (CGTX) reported trailing twelve-month net income of -$23M, reflecting +62.4% year-over-year growth. The company earned $-0.26 per diluted share over the past four quarters.
Looking at the long-term picture, CGTX's historical earnings data spans multiple years. The company achieved its highest annual net income of $757,000 in fiscal 2022.
Cognition Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SAVA (-$106M net income), PRAX (-$327M net income), ACAD ($376M net income, 36.5% margin), CGTX has comparable earnings metrics. Compare CGTX vs SAVA →
CGTX Earnings vs Peers
Earnings metrics vs comparable public companies
CGTX Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$23M | +30.9% | -$48M | $-0.32 | - | - |
| 2024 | -$34M | -31.7% | -$54M | $-0.85 | - | - |
| 2023 | -$26M | -3506.6% | -$51M | $-0.86 | - | - |
| 2022 | $757,000 | +106.5% | -$44M | $-0.74 | - | - |
| 2021 | -$12M | -16.3% | -$29M | $-0.73 | - | - |
| 2020 | -$10M | -44.9% | -$17M | $-0.55 | - | - |
| 2019 | -$7M | - | -$18M | $-0.32 | - | - |
See CGTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CGTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CGTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCGTX — Frequently Asked Questions
Quick answers to the most common questions about buying CGTX stock.
Is CGTX growing earnings?
CGTX EPS is $-0.26, with earnings growth accelerating to +62.4%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-23M.
What are CGTX's profit margins?
Cognition Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are CGTX's earnings?
CGTX earnings data spans 2019-2025. The accelerating earnings trend is +62.4% YoY. Historical data enables comparison across business cycles.